The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI Therapy - PubMed
5 hours ago
- #radiographic progression
- #ARPI therapy
- #prostate cancer
- Radiographic progression (RP) without PSA elevation is a significant pattern in metastatic hormone-sensitive prostate cancer (mHSPC) treated with ARPI therapy.
- 20.1% of patients with castration-resistant prostate cancer (CRPC) experienced RP alone, showing worse overall survival (median 21 vs. 39 months) despite better PSA responses.
- High volume disease (CHAARTED classification) was more common in RP alone patients (94.1% vs. 77.8%) and identified as an independent risk factor (HR 10.3).
- RP alone progression highlights the limitation of PSA-based monitoring and supports routine imaging for early detection of disease progression.